2023
SDI
Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Link Extension
Jacob James Rich, 4-16-2019, JACOB JAMES RICH is a policy analyst at Reason Foundation, and a PhD candidate at the Case Western Reserve School of Medicine, where he conducts research for the Cleveland Clinic. "Medicare for All Means Innovation for None", Reason Foundation, https://reason.org/commentary/medicare-for-all-means-innovation-for-none/, 6-26-2023, //ms
Leading Democratic presidential primary have now almost unanimously endorsed some sort of proposal. Public support to expand the universal health services currently granted to older Americans via Medicare to the entire country is now in the , and the move would replicate publicly-funded universal health care in other developed nations.
Many progressive and moderate Democrats alike have Medicare for All, touting superior access and lower health care costs of single-payer, socialized systems. But health care coverage alone does not mean better health outcomes, and a brief review of Medicare’s real-world results reveals a chief problem of socialized health care — its destruction of innovation.
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Link Extension
Standish Fleming Aug. 4, 2022 The outsized effect of ‘modest’ price controls on pharmaceutical innovation https://www.statnews.com/2022/08/04/outsized-effect-modest-price-controls-pharma-innovation/
Drug price controls in the U.S. Senate are being met with dire warnings that such an approach will stifle innovation, shut off the pipeline of new medicines, and cost lives down the road. Is innovation so fragile that a modest reduction in profits of global giants could seriously impact the supply of new drugs? Small companies originate of all new medicines. Yet the high-cost drugs that lawmakers would target are sold by global giants. Many of them make so much money that they return “excess” profits to shareholders through share buybacks. Congress believes that they can take a portion of those excess profits to balance the federal budget or fight global warming with little risk to productivity. The industry replies that eliminating ”excessive” returns with price controls would remove the financial foundation of the innovation ecosystem. When a company — large or small — considers developing a new treatment, it estimates future returns based on the drug’s ability to lower the cost of caring for patients. Alzheimer’s disease, for example, costs the U.S. per year, which is expected to increase to . Companies developing a drug to treat Alzheimer’s weigh the expected payoff against and an investment of between $1 billion and $3 billion over 10-plus years. Despite those odds, there are in clinical trials for Alzheimer’s disease. What would an effective treatment for Alzheimer’s be worth? Even at $50 billion — a net savings of more than $300 billion per year — it would be a good deal for the country. But would it be feasible with price controls? Humira, the highest grossing medication today, excluding Pfizer’s Covid-19 vaccine. Would the government allow an Alzheimer’s drug to generate more than twice those returns? If Washington, rather than the market, sets the price of drugs, the question of value becomes secondary to political expediency. Companies and investors considering a new drug would not likely risk Alzheimer’s odds knowing that Washington would set a “fair” price for the drug. “Excessive” returns are the business rationale for developing an Alzheimer’s drug. When Gilead introduced the first highly effective drugs to treat hepatitis C, the they generated in one year so threatened budgets that Medicare and Medicaid restricted patients’ access to them. Price controls would have provided a simple solution to the $1,000-per-pill cost of these drugs, but no incentive to develop them in the first place. Experts offer conflicting assessments of the expected drop in the number of drugs produced under with the proposed legislation. My own order-of-magnitude calculation indicates that the projected reduction in the federal deficit — the savings from price controls — of over the next decade could fund the development of 100 to 250 drugs. Researchers with the USC-Brookings Schaeffer Initiative for Health Policy estimated that the industry would lose 10 drugs over 30 years and of undeveloped drugs as likely to “have little impact on the future health of Americans.” A University of Chicago team put the number of lost drugs at and, speaking about cancer (which represents half of total clinical research), concluded that the proposed legislation “will greatly reduce the large activity already taking place in the most active drug class. In turn, this will raise cancer mortality.” The Congressional Budget Office (CBO) appeared to agree with both groups. In January 2022 it forecast a of the expected 1,300 total output of new drugs over the next 30 years. In July, the CBO suggested the loss would be just , then later to . The Brookings, Chicago, and CBO analyses all concluded that the potential loss of new medicines from price controls would be proportional to the loss of revenue, consistent with . The Chicago group forecast an of industry revenue. Would developers of Alzheimer’s drugs similarly trim the pipeline by 26 drugs or, with no way to estimate controlled prices in the future, would they simply walk away? The problem with the “experts’” forecasts is that they are not experts in innovation. Their data showing how pharma has to changes in revenue is dominated by returns to the largest companies, which can make proportional changes to their budgets. But small firms drive the most exciting and potentially valuable drug discovery. Early-stage biotech companies are not miniature versions of multinationals. They serve a specific purpose — innovation — and operate very differently than their larger counterparts.
Reforming the health care system will collapse innovation
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Uniqueness Extension
W. Nicholson Price Ii et al., Rachel E. Sachs & Rebecca S. Eisenberg, 3-30-2022, "New Innovation Models in Medical AI – Washington University Law Review", No Publication, https://wustllawreview.org/2022/03/30/new-innovation-models-in-medical-ai/, 6-26-2023, //ms
Innovation in medical AI is exploding. Every week sees new research papers presenting new algorithms, new companies launching new products, and new possibilities for change. AI products promise to recognize and diagnose skin cancer, to identify eye disease, to find kidney stones, to locate brain hemorrhages, and to quickly detect COVID-19, among many other possibilities. These technologies are likely to change the practice of medicine by increasing the capabilities of care providers in many areas. Products like these also fit—if somewhat uncomfortably—into a capacious understanding of what new medical technology looks like and how we expect it to be regulated. But these are not the only AI products with the potential to transform medicine.
Other AI innovations look quite unlike typical medical devices, yet they also have the potential to transform health care in different ways. A seemingly mundane example is AI-powered scheduling software, which predicts the ebb and flow of patients within the health care system and allocates staff to most effectively meet those patients’ needs. Such products do not directly diagnose or treat patients, but they could increase the capacity of a stretched system and thereby save lives. Other products improve quality of care by predicting the likelihood that a patient will be readmitted to the hospital within a month (so that health care providers can work with patients to prevent that undesirable outcome) or by identifying the risk of a patient developing sepsis (so that rapid-response teams can intervene early). These functions are extremely valuable to the health care system, and all are amenable to AI assistance.
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Uniqueness Extension
Wallace-Wells 23 [David Wallace-Wells, David Wallace-Wells wrote The Uninhabitable Earth and focuses on Tech. He attended Brown University and the University of Chicago, “Suddenly, It Looks Like We’re in a Golden Age for Medicine”, , published June 23, 2023, accessed June 26th, 2023] //hacchs
Suddenly, It Looks Like We’re in a Golden Age for Medicine We may be on the cusp of an era of astonishing innovation — the limits of which aren’t even clear yet. Hype springs eternal in medicine, but lately the horizon of new possibility seems almost blindingly bright. “I’ve been running my research lab for almost 30 years,” says Jennifer Doudna, a biochemist at the University of California, Berkeley. “And I can say that throughout that period of time, I’ve just never experienced what we’re seeing over just the last five years.” A Nobel laureate, Doudna is known primarily for Crispr, the gene-editing Swiss Army knife that has been called “a word processor” for the human genome and that she herself describes as “a technology that literally enables the rewriting of the code of life.” The work for which Doudna shared the Nobel Prize was published more than a decade ago, in 2012, opening up what seemed like an almost limitless horizon for Crispr-powered therapies and cures. But surveying the recent landscape of scientific breakthroughs, she says the last half-decade has been more remarkable still: “I think we’re at an extraordinary time of accelerating discoveries.” The pandemic has exhausted many Americans of medicine, and it has become common to process the last few years as a saga of defeat and failure. And yet these brutal years — which brought more than a million American deaths and probably 20 million deaths worldwide, and seemed to return even the hypermodern citadels of the wealthy West to something like the experience of premodern plague — might also represent an unprecedented watershed of medical innovation. Beyond Crispr and Covid vaccines, there are countless potential applications of mRNA tools for other diseases; a new frontier for immunotherapy and ; a whole new world of weight-loss drugs; new insights and drug-development pathways to chase with the help of machine learning; and vaccines heralded as game-changing for some of the world’s most intractable infectious diseases. “It’s stunning,” says the immunologist Barney Graham, the former deputy director of the Vaccine Research Center and a central figure in the development of mRNA vaccines, who has lately been writing about a “new era for vaccinology.” “You cannot imagine what you’re going to see over the next 30 years. The pace of advancement is in an exponential phase right now.” ‘World-changing’ innovations It is sometimes hard to see the silver lining for the cloud, particularly when it’s as dark as the last three years have been. But at the very center of the American Covid experience, amid all the death and suffering and despite the dysfunction that midwifed it into being, sits what would have stood out, in any previous era, as an astonishing biomedical miracle: the coronavirus vaccines. Drug-development timelines in previous history had swallowed whole decades; experts warned not to expect a resolution for years. But the mRNA sequence of the first shot was designed in a weekend, and the finished vaccines arrived within months, an accelerated timeline that saved perhaps several million American lives and tens of millions worldwide — numbers that are probably larger than the cumulative global death toll of the disease.
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Uniqueness Extension
Andy Acker, CFA Portfolio Manager Apr 13, 2023 Biopharma delivers blockbuster growth https://www.janushenderson.com/en-us/advisor/article/biopharma-delivers-blockbuster-growth/
If you were to look at the performance of biotech stocks over the past two years, you might reason the sector’s growth potential had stalled, if not stopped altogether. Since peaking in February 2021, a broad index that includes small- and mid-cap biotechs – the sector’s main innovation engine – is down nearly 60%. (By comparison, the S&P 500 Index was up 8.5% over the same period.)1 But look past the broad market performance and the story changes dramatically. Last year, revenues for blockbuster drugs (medicines with annual revenues of $1 billion or more) topped $460 billion, up 12% from the prior year. Just five years ago, blockbuster revenues were only half as much. In addition, the number of blockbuster drugs has grown rapidly. In 2022, there were nearly 120 blockbusters. In 2000, that number was just two.2 The biotech sell-off can be attributed to , including valuations that got overstretched during COVID-19 and regulatory uncertainty during a change of leadership at the Food and Drug Administration (FDA). More recently, rising interest rates have been a headwind. But all the while, the sector’s innovation has been gaining momentum – and may soon be too hard to dismiss. This year, more than 75 new medicines are pending approval decisions by the FDA, which could result in a record number of new drug launches for the year. (Currently, the record stands at 59 in 2018.3) What’s more, many of the therapies under review could represent medical breakthroughs that could alter the standard of care – and mark the start of 10-year product cycles.
Global biopharmaceutical companies are solidly growing now.
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Uniqueness Extension
*link & uq combined
Prescient & Strategic Intelligence, September 2022 Biopharmaceutical Market Share Analysis Report by Product Type (Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Vaccines), Therapeutic Application (Oncology, Inflammatory and Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, Cardiovascular Diseases, Neurological Diseases) - Global Industry Demand Forecast to 2030 https://www.psmarketresearch.com/market-analysis/biopharmaceuticals-market#
In 2021, North America was dominant, with a global revenue share of 44%, owing to the high R&D investments, growing adoption of technologically advanced solutions, presence of global players, and their efforts to come up with newer patents. The U.S. holds the major share in this region, which is followed by Europe and Asia-Pacific. With the evolution of biotechnology and conventional pharma sciences, the awareness regarding the best treatments with lower side-effects has also increased. The U.S. leads the global biopharmaceutical R&D list with more than 150,000 studies conducted since 2008, because of the prominence and size of its pharmaceutical sector. Within the country, California accounts for most of the studies, in part, because of its robust tech industry and desire for innovation. Moreover, the U.S. biopharmaceuticals industry has produced more than half the world’s new molecules over the last decade, because of the well-supported intellectual property framework, and government initiatives. Thus, biopharmaceuticals market sales have shown an incredible growth over the past several years in the U.S. The country has been recognized as the innovation capital of the world for life sciences, and its government had put in capital investments since the early stages of pharmaceutical companies. Moreover, it is the biggest investor in health care due to its sizable population, established network of researchers, and expansive health care industry. With regard to medical costs, the U.S. has a free-pricing marketing system. The U.S. prices of biologics are comparatively higher than in other countries, which allows biopharma firms to put in the high R&D funds on these drugs.
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › Innovation DA › 1NC – Syn Bio
Diane Dieuliis, Peter Emanuel and Brian Feeney, 22, (Diane Dieuliis, Peter Emanuel and Brian Feeney, Dr. Peter A. Emanuel is Army Futures Command’s senior research scientist for bioengineering and Brian Feeney is an Army public affairs specialist, located at the Chemical Biological Center, Edgewood, Maryland. Diane Dieuliis is a senior research fellow at the National Defense University., 8-1-2022, No Publication, https://www.nationaldefensemagazine.org/articles/2022/8/1/study-predicts-biotechs-long-term-impact-on-defense, 6-27-2023) SCade
As near-peer nations enter the biological revolution, they will challenge U.S. dominance in the global bioeconomy. This will be a type of gray warfare — a sustained low intensity economic conflict where the interests of multi-national corporations are intertwined with regional politics and the strategic rivalries of global powers. Finally, each nation engaged in the race to a biotechnology future will do so in its own way according to its culture, traditions and political culture. One example is industrial chemicals. Synthetic biology and biomanufacturing will transform the way industry supplies the raw ingredients the U.S. defense sector, along with the broader economy, uses to make materials such as textiles, plastics, lubricants and other consumer goods. Over the next 35 years, bio-products will gradually displace petrochemical production as the dominant means of producing industrial chemical feed stocks. As bioproduction becomes more cost-competitive, adoption will follow, supported by such government programs as the Department of Agriculture’s BioPreferred Program, which helps consumers identify products with biobased substances. The study predicts that the first wave of biomanufactured national security materials will see economically competitive replacements that are “as-is” substitutions. “As is” refers to a chemical produced by the fermentation of sugars instead of the distillation of fossil fuel. Chemically, the product is identical regardless of the way it is produced. This will include high-value defense commodity chemicals such as energetics and fuels, all produced far more cleanly. By the mid-2030s we can expect to see a second wave of biotechnology development — the introduction of reactive and responsive sensory materials that cannot be produced using traditional petrochemical production technologies. These materials will be able to sense, react and respond to the environment. As the Defense Department approaches the year 2050, the study team predicts the commercial introduction of living biomaterials that are composed of bio-engineered living cells that are animate, programmable, interactive and can sustain themselves to some degree. This global transformation will profoundly impact allied defense supply chains. The study team recommends that the department pursue bilateral and multilateral collaborations with its allies and friendly nations to ramp up synthetic biology and biomanufacturing to an industrial scale. These biologically derived materials will transform the kinds of defense systems the nation will be able to create by the mid-21st century. Next, the convergence of biotechnology and material science offers the opportunity to reduce the size, weight, power requirements and cost of sensing technologies while increasing their detection capabilities. For example, synthetic biology allows for the creation of biologically based sensors capable of recognizing actions in the environment, such as the release of a chemical or biological agent. The sensor will be able to respond both by releasing a countermeasure and by notifying other warfighters on the battlefield. Such sensors can be the basis for reactive/responsive surfaces and coatings that will interact with the environment to continually sniff, measure and watch. As with many of the technologies described in this report, the study team recognizes that the path to deploying such systems will be subject to regulatory requirements and must receive public acceptance both at home and in other nations in which they are deployed. The study team recommends that the Pentagon engage partners and allies to develop common guidance and protocols for fielding of biologically based sensors. This will be needed to maintain interoperability and ensure the smooth adoption of next-generation, low-cost sensors throughout the allied forces defending the free world. Another development will be body-worn sensors, which will transform how the military monitors its warfighters force-wide. They will reshape its ability to monitor and predict warfighter health, readiness and performance. They will also lower life-cycle medical costs and improve positive health outcomes. The study team predicts that before 2030, the U.S. military will field wearable sensors that use smartwatches, smart bandages and rings coupled with artificial intelligence and machine learning to predict potential infection, detect early onset of physical stressors in real-time and limit disease spread. Soon after, widespread adoption of wearables systems by the general populace will surge as it is pushed by commercialization. By 2040, much of the U.S. population will wear a medical tracking device. Another trend will be food security. Over the next 30 years, the planet’s population will likely continue to grow, and climate change will shift the locations of the planet’s grain belts. The ability of a nation to export agricultural products could become a powerful geopolitical tool carrying economic, political and military advantage. By 2040, shifting arable geographies will alter economies and could serve as flashpoints for military conflicts. Food scarcity aggravated by its uneven distribution along the world’s north-south divide will emerge a pressing national security issue. Future U.S. defense leadership must consider how to form interagency partnerships that will address agricultural biotechnology as a power for peace. Closely related is resource competition. To manufacture electronics, medical devices and advanced weapons systems, the defense industry is reliant upon metals such as lithium, gallium and cobalt in addition to rare earth elements such as lanthanide, europium and terbium. However, foreign countries — some of them hostile to U.S. interests — control a large portion of the planet’s known metal reserves. This is cause for concern. The nation needs future access to a reliable supply chain for these critical metals. The United States only controls 1 percent of global rare earth elements reserves while China and Russia together control 48 percent. Increasing consumer demand will accelerate their depletion causing competition between the United States and these adversary nations. Current projections are that several commodities will reach a tipping point after 2035, including the rare earth elements, lead, tin, cobalt, copper, zinc, manganese and phosphates. To accommodate demand and provide secure supply chains, industry will need to extract resources from locations that were previously deemed uneconomical such as the deep sea, and even off-world in facilities placed into Earth orbit. Biotechnology will provide much of the answer by providing cost effective and eco-friendly ways to more efficiently extract and separate critical minerals from bulk, raw mined sources or reclaim them from recycled systems. The study team recommends that the Defense Department assess how biotechnologies can be used to improve reclamation of rare earth elements and other critical resources. This assessment should include how industrial bio-extraction might help return mining separation operations to domestic companies by reducing environmental impacts. The department will also need to assess where within the defense enterprise biotechnology-enhanced mining can be employed to augment traditional supplies of critical materials and to lower costs. Biotechnology will also transform medicine in future wars by removing many of the human body’s current limitations. Through changes such as enhancing the human microbiome to creating brain-computer interface technologies for human-machine teaming, a warfighter’s body will truly be transformed into a “human weapons system.” At the same time, the armed force’s medical care will be vastly improved by new medical treatments and therapies. By 2035, genetically engineered therapies will enable us to treat a wider range of diseases and greatly augment our body’s natural ability to heal from injury. By 2040, off-world medicine and biotechnology will sustain a lucrative commercial market that will include personalized-tissue engineering and synthetic organ and limb replacements. The Defense Department will have the ability to create synthetic organs and deploy medical care to austere environments. It will be an innovator and early adopter of medical treatments and trauma technologies. Over the next three decades, spurred by the commercialization of space, NASA will move from missions of discovery to embrace the sustainment of construction and production operations on off-world locations. Rather than visit another planet and taking surface samples, NASA will be building and operating small high-tech factories in space or on another planet to produce next-generation materials that can only be made, or are more efficiently made, in near-zero gravity. The humans who are needed in space to build and operate these factories will need to be housed, fed, protected from space hazards such as radiation and, most difficult of all, provided with medical care. The study team recommends that the Pentagon and NASA co-sponsor an interagency deep-dive study that considers micro-gravity medicine, how medical technologies can be adapted to remote and austere environments, how to develop reactive and responsive sensors and how to develop plans for future bio-materials requirements. These technological advancements affect matters of war and peace. Even if a biotechnology application has no immediate apparent strategic value to national security, it can still serve as a flashpoint for political and social conflict in hot spots around the world and draw defense agencies into the fray. In addition, the different parties that advance biotechnology — such as commercial industries — will have differing priorities. The parties creating advanced bio-products will vary, too, as the barriers to entry continuously lower. The prospect of a radical non-state organization getting this technology will be an ever-growing possibility that will bear ongoing scrutiny. Culture eventually catches up with technology. Early amateur photographers, ham radio enthusiasts and model rocketry communities were all met with apprehension and ridicule in their infancy as was in vitro fertilization when it was introduced in the 1970s. Today, all these technologies have become accepted by mainstream society. For all these reasons, the study team recommends that intelligence agencies, homeland security and defense planners make biotechnology a central component of a regular technology watch, both domestically and globally. A strength of U.S. national security is the willingness to look over the horizon and plan for what the future will bring. There is an inflection point now with the coming biotechnology revolution. The convergence of biotechnology, automation and AI will disrupt and transform all facets of life and, by the year 2050, will profoundly alter how the Defense Department executes its mission.
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › Innovation DA › 1NC – Syn Bio
Miruna Sasu, Ph.D, President and CEO of COTA, Inc. May 2 2023 WILL THE INFLATION REDUCTION ACT STIFLE PHARMA INNOVATION? https://www.pharmalive.com/will-the-inflation-reduction-act-stifle-pharma-innovation/
While lower drug prices are a victory for patients, the legislation’s specific mechanisms for controlling costs could have dire unanticipated consequences for pharmaceutical innovation. Pharma companies looking to compensate for lower sales revenues may turn to trimming down their biggest cost centers — drug discovery and clinical trials — as well as any budget dedicated to improving efficiencies in their business. The result could be fewer new drugs, less innovation, and reduced access to breakthrough therapies, particularly for populations that already experience health equity barriers. To maintain the pace of innovation and ensure equitable access to new therapies over the coming decades, pharma companies will need to embrace new data-driven strategies and partnerships that bolster the drug discovery pipeline even in the face of financial uncertainty. Dozens of new therapies are approved every year in the United States, thanks to significant advances in clinical knowledge and the data science underpinning the innovation process. Over the past decade, global regulators 410 different drugs, approximately three-quarters of which are approved in the U.S. first. Pharma companies spend billions of dollars making these drugs for patients who often have exhausted all other options, and they must be careful about selecting which molecules to pursue through the expensive, complex, and time-consuming development process. Currently, pharma companies tend to enjoy once these therapies make it to market — and just like every other business, they would like to retain as much of their revenues as possible. Giving Medicare the power to negotiate drug prices may cut into these margins, resulting in pharmaceutical companies reducing the number of molecules they invest in.
Biopharmaceutical industry thriving now and innovation fosters growth of novel biologics or syn bio.
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › Innovation DA › 1NC – Syn Bio
Contralant, March 20, 2023 The new frontiers of pharmaceutical innovation – according to investors https://www.pharmaceutical-technology.com/sponsored/the-new-frontiers-of-pharmaceutical-innovation-according-to-investors/
But there are some positive signs. The Covid-19 pandemic created a new appetite for pharmaceutical innovation – dulled by recent economic troubles, but ravenous compared to pre-2020 averages. The mRNA technology that enabled the largest and fastest vaccine rollout in history is the tip of the innovation iceberg. Research – and money – going into even more advanced gene therapies is ramping up. In addition, mega deals – investments worth $100m or more – are on the rise. Contrast 2022 with 2019. In addition to a higher overall volume of investment, mega-investors are staking greater claims in pharmaceutical innovation. On average, mega-deals made up 45% of investments in 2022, contrasting with just 29% of investments in 2019. The venture capital world has settled around a new equilibrium where investors are willing to spend more money more often on the innovations of the future. Some regions and therapies have become particularly fertile growth areas; entrepreneurs who are in the know stand to benefit enormously.
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › Innovation DA › 1NC – Military Readiness
Michael E. O'Hanlon and James N. Miller 10-4-2019. (Michael E. O'Hanlon - Director of Research - Foreign Policy Director - Strobe Talbott Center for Security, Strategy, and Technology Co-Director - Africa Security Initiative Senior Fellow - Foreign Policy, Strobe Talbott Center for Security, Strategy, and Technology Philip H. Knight Chair in Defense and Strategy and James N. Miller - Former Under Secretary of Defense for Policy - Obama administration Senior Fellow - Harvard’s Belfer Center for Science & International Affairs Senior Fellow - Johns Hopkins University’s Applied Physics Laboratory . "Why we need a more modern and ready military, not a larger one." Brookings. Web. 10-4-2019. accessed 3-5-2023 < https://www.brookings.edu/blog/order-from-chaos/2019/10/04/why-we-need-a-more-modern-and-ready-military-not-a-larger-one/ >.) MSUCB
By contrast, quality must improve, and modernization must intensify. That is not because the U.S. military is obsolescent. Rather, the pace of innovation in key areas of military technology, and the way in which vulnerabilities in our existing military could be exploited by Russia or China, require it. If we fail to make the U.S. military more modern, resilient, lethal, and survivable, the perception could grow that relative American combat power was fading — or that the American military had developed systemic vulnerabilities that an enemy could exploit to produce catastrophic failure. Deterrence could weaken. War could result. And we could quite possibly even lose such a war. The years 2020-40 seem likely to see even more change in the technologies, and the character, of warfare than have recent decades. For the years 2000-20, revolutionary technological change occurred mainly in various aspects of computers and robotics. For the next two decades, those areas will remain fast-moving, and they will be joined by various breakthroughs in artificial intelligence (AI) including the use of big data. The battlefield implications in domains such as swarms of robotic systems usable as both sensors and weapons may truly come of age. In addition, progress in laser weapons, reusable rockets, hypersonic missiles, unmanned submarines, biological pathogens, and nanomaterials may occur rapidly. The sum total may or may not add up to a revolution. But the potential cannot be dismissed. The rise of China and the return of Russia supercharge the competition and raise the strategic stakes. The marriage of rapid technological progress with hegemonic change could prove especially potent. The return of great-power competition during an era of rapid progress in science and technology could reward innovators and expose vulnerabilities, much more than has been the case in the 21st century to date. Not every existing Department of Defense weapons program is equally defensible, of course. Some programs should be reassessed, or delayed, in order to make room for more survivable and effective systems — for example, reducing procurement of surface ships in favor of attack submarines and unmanned undersea vehicles for the Navy, and emphasizing longer-range aircraft more than fighters for the Air Force as well as the Navy. On balance, however, in broad strokes and in overall resource requirements, the Pentagon agenda for modernization makes sense. It is important to prioritize, and preserve, it. Today’s already-excellent American military is big enough to meet the reasonable requirements of ongoing commitments and great power competition — provided, that is, that it improves further. It needs to repair readiness. Most of all, it must be modernized for greater lethality, and made more resilient and survivable against the kinds of precision-strike, cyber, anti-satellite, and other asymmetric attacks future adversaries would be sure to employ. We need to keep our eye focused clearly on the ball, and our resource allocations focused clearly on the strategy. We need a more modern and ready force, not a larger one.
1NC – Syn Bio
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › Innovation DA › 1NC – Military Readiness
EC, 19, (Embassy Of Canada To The United States, 5-8-2019, Center for the Study of Traumatic Stress, Personalized Medicine in Mental Health and Performance, https://www.cstsonline.org/education-and-training/conferences/nato-panel/personalized-medicine-in-mental-health-and-performance, 6-27-2023) SCade
The medical field is committed to delivering evidence-based care, but the evidence used is often from population-wide studies that does not always allow for tailored approaches reflective of an individual patient’s biological makeup, history, and responses to environmental factors. This may contribute to less than optimal prevention strategies, diagnostics, and responses to treatments. However, there have been great advances in some areas of medicine such as oncology that use Precision Medicine to customize treatment approaches based on an individual patient’s profile in the context of evidence-based care. The use of Precision Medicine will ultimately have a positive impact on military readiness and performance. The main objective is to harness and encourage new advances in personalized approaches to optimize: 1) mental health, including ensuring medical readiness, prevention/diagnosis/treatment of disorders, and return to duty; and 2) mental health aspects related to military-relevant mission performance.
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › Innovation DA › 1NC – Military Readiness
Jonathan D Grinstein, PhD -April 26, 2023 Big Pharma Leadership Decries the Inflation Reduction Act https://www.genengnews.com/gen-edge/big-pharma-leadership-decries-the-inflation-reduction-act/
By contrast, the panel rallied enthusiastically in favor of the role of artificial intelligence (AI) in drug discovery. Hardy said AI is transforming Genentech’s R&D activities. “We’re at 300 computational scientists at Genentech in a research organization of 2,400—it’s a very large proportion of our workforce that’s comparable in size to our teams of organic chemists,” he said. “We see this as unlocking tremendous amounts of innovation in the future, and we are just starting to realize new types of partnerships that we can have to take advantage of this.” Amgen’s Bradway sang a similar tune. “The protein folding work, starting with AlphaFold in 2021, was a really big moment for us as an organization and has already led to a number of exciting insights that otherwise might have taken a lot longer,” said Bradway. “In the last few weeks, we’re beginning to recognize how large language models can help us be more productive efficiently.” McMurry-Heath focused on AI’s role in improving precision in patient selection in clinical trials. “AI is going to help us with one of our biggest barriers—cost,” she said. “AI is going to shrink clinical trials, allowing us to really pinpoint which patients are needed to prove the new drug or compound is safe and effective and hopefully cut out a lot of the noise. I’ve met CEOs that say 90% of their costs and time going to market is clinical trials. Clinical trials are not without risk to the patients involved, whether they’re in a placebo arm or the treatment. “Whatever knowledge we can use to make sure that we are only testing the smallest number of patients needed to get an answer that’s reproducible and reliable, [that’s what] we should be striving for.”
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › Innovation DA › 1NC – Military Readiness
Miruna Sasu, Ph.D, President and CEO of COTA, Inc. May 2 2023 WILL THE INFLATION REDUCTION ACT STIFLE PHARMA INNOVATION? https://www.pharmalive.com/will-the-inflation-reduction-act-stifle-pharma-innovation/
While lower drug prices are a victory for patients, the legislation’s specific mechanisms for controlling costs could have dire unanticipated consequences for pharmaceutical innovation. Pharma companies looking to compensate for lower sales revenues may turn to trimming down their biggest cost centers — drug discovery and clinical trials — as well as any budget dedicated to improving efficiencies in their business. The result could be fewer new drugs, less innovation, and reduced access to breakthrough therapies, particularly for populations that already experience health equity barriers. To maintain the pace of innovation and ensure equitable access to new therapies over the coming decades, pharma companies will need to embrace new data-driven strategies and partnerships that bolster the drug discovery pipeline even in the face of financial uncertainty. Dozens of new therapies are approved every year in the United States, thanks to significant advances in clinical knowledge and the data science underpinning the innovation process. Over the past decade, global regulators 410 different drugs, approximately three-quarters of which are approved in the U.S. first. Pharma companies spend billions of dollars making these drugs for patients who often have exhausted all other options, and they must be careful about selecting which molecules to pursue through the expensive, complex, and time-consuming development process. Currently, pharma companies tend to enjoy once these therapies make it to market — and just like every other business, they would like to retain as much of their revenues as possible. Giving Medicare the power to negotiate drug prices may cut into these margins, resulting in pharmaceutical companies reducing the number of molecules they invest in.
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › Innovation DA › 1NC – Military Readiness
Contralant, March 20, 2023 The new frontiers of pharmaceutical innovation – according to investors https://www.pharmaceutical-technology.com/sponsored/the-new-frontiers-of-pharmaceutical-innovation-according-to-investors/
But there are some positive signs. The Covid-19 pandemic created a new appetite for pharmaceutical innovation – dulled by recent economic troubles, but ravenous compared to pre-2020 averages. The mRNA technology that enabled the largest and fastest vaccine rollout in history is the tip of the innovation iceberg. Research – and money – going into even more advanced gene therapies is ramping up. In addition, mega deals – investments worth $100m or more – are on the rise. Contrast 2022 with 2019. In addition to a higher overall volume of investment, mega-investors are staking greater claims in pharmaceutical innovation. On average, mega-deals made up 45% of investments in 2022, contrasting with just 29% of investments in 2019. The venture capital world has settled around a new equilibrium where investors are willing to spend more money more often on the innovations of the future. Some regions and therapies have become particularly fertile growth areas; entrepreneurs who are in the know stand to benefit enormously.
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › CP Solvency › States CP Solvency
MICHAEL LIGHTY JANUARY 27, 2022 States Now Hold the Key to Making Medicare for All a Reality https://inthesetimes.com/article/medicare-for-all-single-payer-healthcare-california-new-york
Winning single payer in key states like New York and California could help demonstrate that the system works and compel Democrats in Congress to act. This is a political strategy reflecting the reality that Medicare for All advocates face federally. State organizing helps build the base that will be required to ultimately win guaranteed healthcare for all. And, perhaps surprisingly, we now have strong opportunities to do just that.
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › CP Solvency › States CP Solvency
MICHAEL LIGHTY JANUARY 27, 2022 States Now Hold the Key to Making Medicare for All a Reality https://inthesetimes.com/article/medicare-for-all-single-payer-healthcare-california-new-york
A significant but under-reported story in the field of healthcare reform is the growing effort to establish Medicare for All-type systems at the state level. Across the country, elected officials and movement organizers have joined forces to make single payer a reality. And they’re building momentum. In New York, after years of conservative control of the state Senate, progressives who campaigned in 2018 in support of the New York Health Act — a bill that would create a Medicare for All-style system — were elected to office. With these victories, a majority of legislators in both the state Assembly and Senate have now co-sponsored the bill. But in May 2021, a combination of privately reluctant legislators and some resistant unions, along with a lack of gubernatorial support, convinced the Democratic leadership not to bring the bill up for a vote in either house of the legislature. In response, the Campaign for New York Health — a coalition organizing for universal coverage — has promoted stories of people denied care because of insurance company practices and costs, conducted canvasses in key legislative districts, and reached out to unions and union members to address their concerns. The bill’s authors are also considering further amendments, and plan to continue their fight to pass the legislation. In California, a nurse-led campaign has moved the single-payer bill AB 1400 onto the floor of the state Assembly for a vote in late January. A broad labor-community coalition — Healthy California Now — has organized petitions, letter-writing campaigns, and events around the state to urge Gov. Gavin Newsom (D-CA) to fulfill his campaign promise of enacting single payer, universal healthcare. This month, he proposed to cover all undocumented people through the state’s Medi-Cal program. And in April, Newsom’s universal healthcare commission is expected to recommend a “unified financing” (akin to Medicare for All) healthcare system. Advocates in Washington State, meanwhile, are currently recruiting petition captains for a signature-gathering effort to put a Medicare for All-type healthcare system on the November ballot, in a campaign called “Whole Washington.” Also in Washington, the organization-based coalition Healthcare is a Human Right is urging the state’s task force on universal healthcare to adopt a single-payer approach as it advocates for a bill to rein in health entity mergers and acquisitions that restrict access to care and pad the profits of corporate healthcare providers. In Oregon, Health Care for All, a coalition of advocates, unions and community based organizations, is organizing to move the state’s universal healthcare task force toward a single-payer model. In November, Oregon voters will consider the HOPE amendment, sponsored by the coalition, to establish healthcare as a fundamental right in the state. Rhode Island activists, working with the Providence chapter of the Democratic Socialists of America, have helped organize testimony in the state legislature, social media campaigns and pressure on state legislators to pass a state single payer bill, and are now building awareness around the effort to reach working people through the institutions they participate in, such as unions and faith organizations. In Minnesota, advocates led by labor union leaders — in particular the Minnesota Nurses Association — are signing up legislative supporters in preparation for favorable majorities in 2023 to move single payer legislation, which was considered this year in a House committee but has since been blocked by the Republican majority in the state Senate. In Massachusetts, advocates are organizing ahead of the November 2022 ballot, which will ask residents whether they want local officials to back single payer, in districts where state representatives aren’t currently supporting a Medicare for All system. This effort is intended, in part, to inform constituents if their official is not a cosponsor of the current single payer bill in the state, and to help them take action, educate the district about Medicare for All, and demonstrate the wide support for universal healthcare. Strategy shift In the context of the stymied efforts to expand Medicare at the national level, these state efforts show where the real action is. If we include the recent successful voter-led efforts in states such as Montana, Missouri and Maine to expand Medicaid, the terrain for winning universal, publicly-financed comprehensive healthcare looks increasingly favorable. The current dichotomy between state and federal prospects for Medicare for All style reform reflects a difficult truth that motivated progressives in 2016 and 2020: it takes a president who champions single payer for it to have a chance politically at the national level. In its Build Back Better bill, the Biden administration has not even fought for the modest, incremental promises of the president’s campaign, such as lowering the Medicare eligibility age to 60 and including a public option. Instead of legislative action to expand healthcare as a public good, the administration is allowing private equity and other for-profit entities to have an expanded role within Medicare, continuing a “direct contracting” program begun by former President Trump. In fact, the most popular elements of the House-passed Build Back Better bill are Medicare expansion and prescription drug price negotiations. Medicare for All polls at around 70 percent support among Democrats, majority support among independents, along with a good plurality of Republicans (mostly lower income). Yet not even a deadly pandemic has moved federal lawmakers closer to passing guaranteed healthcare for all. The Covid-19 crisis has revealed long-standing healthcare inequities based on race, exposed inadequate workplace protection and safety measures, made clear that employment-based health insurance is not reliable and shown the need for a more robust public health system. And still, we have the continuing disconnect between the need for a Medicare for All system and the lack of legislative action on it in Congress. But the problem is not just the lack of strong leadership from the White House or Democratic leadership. The movement for Medicare for All at the federal level has also not yet created sufficient alliances with other movement groups and the electoral leverage and working-class organization necessary to overcome the money and power of the pharmaceutical companies, the insurance industry and the corporate hospital chains. These are the key institutional players that dictate health policy. Private equity has become a major stakeholder in the healthcare industry and a powerful lobbying force, leading to Wall Street control over our access to healthcare.
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › CP Solvency › States CP Solvency
, JD, PhD 2019 States as Policy Laboratories: The Politics of State-Based Single-Payer Proposals 2019 November; 109(11): 1511–1514. Published online 2019 November. doi: PMCID: PMC6775896 PMID: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775896/
Although single-payer proposals at the national level have only recently received their first congressional committee hearing, there are several states in which single-payer proposals have received serious consideration. Vermont, for example, enacted legislation in 2011 that put them on the path to single payer (although that effort was eventually dropped in 2014). Colorado voters considered (but defeated) a single-payer referendum in 2016, as did voters in Oregon in 2002. More recently, the California state senate passed a single-payer bill in 2017 that garnered the support (at least during the campaign) of that state’s newly elected governor, Gavin Newsom. And in New York, single-payer supporters saw a window of opportunity after the November 2018 election results in which the Democrats took control of the state senate, following several years in which a Republican senate had blocked an assembly passed single-payer bill.
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › DA Links › Links – Politics
, PhD 2019 November; 109(11): 1497–1500. Published online 2019 November. doi: PMCID: PMC6775897 PMID: Lessons From the Long and Winding Road to Medicare for All https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775897/
Cohering the byzantine, fragmented collection of governmental and private insurance programs into a single national plan is an extraordinarily formidable task. Each piece of our health care patchwork has influential political interests that are fiercely protective of the status quo and resistant to the major disruption in current arrangements that Medicare for all would require. Moreover, the proliferation of alternative coverage sources means that moving to a single federal plan would require more than 200 million people, many of whom are satisfied with their present arrangements, to change insurance. Even Medicare beneficiaries are subject to political attacks against Medicare for all that claim it would threaten their existing access to medical services. Single-payer reform would also require, if employer-sponsored insurance is to be substantially displaced by a government plan, supplanting private with public financing. Although single payer has efficiencies that could produce considerable savings, those savings do not obviate the enormous political challenge of substituting highly visible (and high) taxes for often obscured employer premium contributions.
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › DA Links › Links – Politics
, PhD 2019 November; 109(11): 1497–1500. Published online 2019 November. doi: PMCID: PMC6775897 PMID: Lessons From the Long and Winding Road to Medicare for All https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775897/
Second, proposals to establish a federally run national health insurance program, with the important exception of Medicare, have consistently failed to come anywhere close to passing Congress. Their repeated defeat underscores the daunting barriers that have long stood in the way of single-payer plans, including intense opposition from health system stakeholders, Americans’ ideological ambivalence about government, fear of socialized medicine, and fragmented political institutions that make enactment of ambitious reform legislation difficult and give opponents multiple opportunities to block reform.
2023
SDI
Negative
MSDI Case Neg vs Medicare for All › DA Links › Links – Politics
David Rosenbloom, PhD, is a professor at the Boston University School of Public Health. September 07, 2020 HUMAN RIGHTS The Precarious Path to Universal Health Coverage https://www.americanbar.org/groups/crsj/publications/human_rights_magazine_home/health-matters-in-elections/the-precarious-path-to-universal-health-coverage/
Medical care policy is controversial because it is redistributive. Those of us who are healthier and wealthier help pay for the care of those who are sicker or poorer. Often the transfers are not transparent and therefore rarely set off political firestorms. A majority of hospitals in the country report they lose money or barely break even on Medicaid and Medicare patients. However, hospitals typically make about a 30 percent profit on employer-sponsored insurance to make up for these losses—an invisible redistribution. Progressive federal and state tax regimes redistribute wealth when some of that tax money is used to pay Medicaid expenses. Those of us with higher salaries pay more in Medicare payroll tax than lower-wage workers, but we are all entitled to the same benefits. As soon as the Medicare for All debate among Democrats got into the details of how it would be paid for, the redistributive aspects became transparent and open to political attack as “socialized medicine.” Other factors will also shape the health care policy debates in 2021: COVID-19, past policy choices that determine how—and how much—we pay for medical care, and efforts to address systemic health disadvantage among Black and brown Americans.